Trial reportDiabetes care2010
Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.
Trial report in Diabetes care, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Pooled it
- Trial
- Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.Heart and vessels · 2013Trial
- Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis.Clinical and experimental nephrology · 2013Trial
- The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study.PloS one · 2013Trial
- [Consensus recommendations on the diagnosis and treatment of hyperkalemia of the Austrian Society of Nephrology 2026].Wiener klinische Wochenschrift · 2026Review
- The burden of hyperkalaemia in chronic kidney disease: a systematic literature review.Clinical kidney journal · 2025Article
- Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design.Kidney international reports · 2021Article
- Therapeutic Renin Inhibition in Diabetic Nephropathy-A Review of the Physiological Evidence.Frontiers in physiology · 2020Review
- New therapeutic agents in diabetic nephropathy.The Korean journal of internal medicine · 2017Review
- Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus?American journal of translational research · 2015Article
- Direct renin inhibition in chronic kidney disease.British journal of clinical pharmacology · 2013Review
- Role of single-pill combination therapy in optimizing blood pressure control in high-risk hypertension patients and management of treatment-related adverse events.Journal of clinical hypertension (Greenwich, Conn.) · 2012Review
- Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease.BMC nephrology · 2012Article
- Approach to cardiovascular disease prevention in patients with chronic kidney disease.Current treatment options in cardiovascular medicine · 2012Article
- Oral renin inhibitors in clinical practice: a perspective review.Therapeutic advances in chronic disease · 2012Article
- Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension.Expert review of cardiovascular therapy · 2012Review
- Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2011Review
- Aliskiren as an add-on treatment reduces albuminuria in patients with diabetes.Nature reviews. Nephrology · 2011Article
- Emerging concept of anti-hypertensive therapy based on ambulatory blood pressure profile in chronic kidney disease.American journal of cardiovascular disease · 2011Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveProteinuric diabetic patients with reduced glomerular filtration rate (GFR) are at high risk of renal and cardiovascular disease progression and treatment-related adverse events. This post hoc analysis assessed the efficacy and safety of aliskiren added to the maximal recommended dose of losartan according to baseline estimated GFR (eGFR) (stage 1-3 chronic kidney disease [CKD]). RESEARCH DESIGN AND
methodsIn the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) study, 599 hypertensive patients with type 2 diabetes and nephropathy received 6 months of aliskiren (150 mg daily titrated to 300 mg daily after 3 months) or placebo added to 100 mg losartan and optimal antihypertensive therapy. Exclusion criteria included eGFR<30 ml/min per 1.73 m2 and serum potassium>5.1 mmol/l.
resultsBaseline characteristics were similar between treatment groups in all CKD stages. The antiproteinuric effects of aliskiren were consistent across CKD stages (19, 22, and 18% reduction). In the stage 3 CKD group, baseline serum creatinine levels were equal, but renal dysfunction, prespecified as a postrandomization serum creatinine elevation>176.8 μmol/l (2.0 mg/dl) occurred more frequently in the placebo group (29.2 vs. 13.6%, P=0.032). Serum potassium elevations>5.5 mmol/l (based on a single measurement) were more frequent with aliskiren (22.5 vs. 13.6%) in stage 3 CKD. Adverse event rates were similar between treatments, irrespective of CKD stage.
conclusionsAliskiren added to losartan reduced albuminuria and renal dysfunction and was well tolerated, except for hyperkalemia (stage 3), independent of baseline CKD stage in patients with type 2 diabetes, hypertension, and nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.